A study conducted in Australia has concluded that a person’s inherited risk factors for melanoma should be considered when developing self-examination and surveillance programs.
A study conducted in Australia has concluded that a person’s inherited risk factors for melanoma should be considered when developing self-examination and surveillance programs.
With more than 10,000 deaths and 76,000 new diagnoses, melanoma is among the leading causes of cancer-related deaths, according to the American Cancer Society. New treatment options, particularly those that are immune-based, and early diagnosis could together go a long way in improving outcomes in this patient population. With this in mind, people at higher risk of melanoma are urged to consider having regular surveillance and be trained on self examination.
Authors of the present study, called "The Melanoma Patterns of Care" and published in JAMA Dermatology, aimed to characterize the clinical features in melanoma that are associated with a person’s risk for disease development; these include many nevi, prior history of melanoma, and family history of melanoma. The study enrolled 2727 patients with melanoma, who were diagnosed with an in situ or invasive primary melanoma, between October 2006 and October 2007.
A total of 1052 patients were identified as higher risk due to a family history of the disease, multiple primary melanomas, or many nevi. Compared with the low-risk patients (who did not have any of the risk factors), patients in the higher-risk group were younger when diagnosed (62 versus 65 years, P <.001). When specific risk factors were considered, however, the authors found that the age at diagnosis varied: it was 56 years for patients with a family history, 59 years for those with many nevi, and 69 years for those with a previous melanoma.
Further, among those at a higher risk, multiple nevi most likely meant they would have melanoma on the trunk region of their body (41% vs 29%, P <.001), a family history increased their likelihood of developing melanoma on the limbs (57% vs 42%, P <.001), while those with a history of melanoma were more likely to have melanoma on the head and neck (21% vs 15%, P  = .003).
Based on their findings, the authors concluded that education about self examination could be tailored to a person’s risk factors, such as highlighting areas on the body where melanoma is most likely to occur. The starting age for surveillance could also be tailored accordingly.
Reference
Watts CG, Madronio C, Morton RL. Clinical features associated with individuals at higher risk of melanoma: a population-based study [published online November 9, 2016]. JAMA Dermatol. doi:10.1001/jamadermatol.2016.3327.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More